European Pharmaceutical Review Issue 2 2019

This issue questions whether companies are sufficiently investing in regulatory intelligence software and what the potential consequences of Brexit might be for locations outside of the UK and EU. The issue also features articles on microbiology, formulation and biopharma, courtesy of our in-depth focus sections; as well as outlining the essentials in QbD, process and analytical controls.

Included in this issue:

    Are you giving regulatory intelligence the platform it deserves?
    Jürgen Hönig and Rob Williams, PharmaLex
    Potential impact of Brexit outside the UK/EU
    Paul Ranson, Morgan Lewis
    Emerging NMR techniques as advanced tools for characterising biological parenteral products
    Yongchao Su and Wei Xu, Merck & Co and Bruce Yu, University of Maryland School of Pharmacy
  • PAT
    Essentials in QbD, process and analytical controls
    Thomas A. Little, President/CEO Thomas A. Little Consulting, BioAssay Sciences
    Expecting the unexpected
    James Mellman, Novartis
    It’s not just about the science 
    Paul J Newby, Alice Laures and Lisa Wysocki, GlaxoSmithKline

This Issue of European Pharmaceutical Review is restricted - login or subscribe free to access

EPR Issue 1 2024Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • bi-monthly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here